222 related articles for article (PubMed ID: 36403110)
1. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
[TBL] [Abstract][Full Text] [Related]
2. Teaching neuroimages: dyspnea as a presenting manifestation of amyloid myopathy.
Ghosh PS; Thaera GM; Tracy JA
Neurology; 2013 Dec; 81(24):e184. PubMed ID: 24323446
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
5. [A case of amyloid myopathy diagnosed during the treatment of myopathy associated with anti-signal recognition particle antibodies].
Kawakami N; Katsuyama Y; Hagiwara Y; Yoshida H; Kim K; Harada K
Rinsho Shinkeigaku; 2017 Apr; 57(4):168-173. PubMed ID: 28367947
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.
Ono E; Ishii A; Higashi Y; Koita N; Ayaki T; Tanigaki K; Takayanagi S; Kondo N; Sakai K; Endo S; Yokoi H; Matsubara T; Minamiguchi S; Nishino I; Takahashi R; Yanagita M
BMC Nephrol; 2021 Feb; 22(1):74. PubMed ID: 33639890
[TBL] [Abstract][Full Text] [Related]
7. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
[TBL] [Abstract][Full Text] [Related]
8. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
9. Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: Case report.
Draghici M; Jercan A; Badelita SN; Irimia RM; Bastian AE; Dobrea C; Popescu M; Coriu D
Medicine (Baltimore); 2021 Dec; 100(51):e28267. PubMed ID: 34941106
[TBL] [Abstract][Full Text] [Related]
10. Axillary Lymphadenopathy as an Initial Presentation of Systemic Amyloidosis: A Case Report and Literature Review.
Kumar S; Grell GR; Joseph G; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221133191. PubMed ID: 36300416
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
16. Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: An autopsy case.
Tanabe H; Maki Y; Urabe S; Higuchi I; Obayashi K; Hokezu Y
Muscle Nerve; 2015 Dec; 52(6):1113-7. PubMed ID: 26179325
[TBL] [Abstract][Full Text] [Related]
17. [Myopathy and mixed hyperlipoproteinemia as the first symptom of systemic AL-amyloidosis].
Tosovský M; Soukup T; Bradna P; Maisnar V; Tycová V; Toms J; Prixová M
Vnitr Lek; 2008 Oct; 54(10):1014-9. PubMed ID: 19009771
[TBL] [Abstract][Full Text] [Related]
18. Amyloid myopathy presenting with distal atrophic weakness.
Smestad C; Monstad P; Lindboe CF; Mygland A
Muscle Nerve; 2004 Apr; 29(4):605-9. PubMed ID: 15052628
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
[TBL] [Abstract][Full Text] [Related]
20. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
